Dupilumab therapy reduced atopic dermatitis symptoms in pediatric population, finds study

The participants who received dupilumab showed substantial improvements in caregiver-reported AD symptoms and quality of life when compared to the ones who received a placebo. When compared to the placebo group, the dupilumab group showed a least square mean (LSM) drop of -3.6 from baseline on the Worst Scratch/Itch Numerical Rating Scale (WSI-NRS) in week 1 and maintained it through week 16.

Also, 48% of the dupilumab group satisfied the criterion for a clinically relevant change in WSI-MRS, against 9% in the placebo group. The dupilumab group improved their sleep quality numerical rating scale (NRS) by 2.0 points from baseline to week 16 when compared to a 0.3 point change in the placebo group for both individuals and caregivers. The number of patients declaring no days or 1-2 days of itching in the previous 7 days differed more in the dupilumab group from baseline than in the placebo group.

Similarly, the proportion of patients stating no days and 1-2 days of sleep disturbances in the previous 7 days differed more between week 16 and baseline. Overall, Dupilumab helped individuals with AD symptoms and their families/caregivers' quality of life.

Source:

Paller, A. S., Silverberg, J. I., Simpson, E. L., Cork, M. J., Arkwright, P. D., Chen, Z., Bansal, A., Prescilla, R., Wang, Z., & Marco, A. R. (2024). The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study. In Journal of the American Academy of Dermatology. Elsevier BV. https://doi.org/10.1016/j.jaad.2024.09.039